Beijing Dongfang Biotech Co., Ltd.
Clinical trials sponsored by Beijing Dongfang Biotech Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New diabetes shot every two weeks could rival weekly drug Results expected Oct 2026 (estimated)
-
New diabetes shot every two weeks could rival weekly drug
Disease control OngoingThis phase 3 trial compares two doses of an experimental drug called JY09 against the approved drug dulaglutide in 600 adults with type 2 diabetes not well controlled by metformin alone. Participants receive either JY09 every two weeks or dulaglutide once a week for 54 weeks. The…
Phase 3 • Sponsor: Beijing Dongfang Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:59 UTC
-
New biweekly shot could help control blood sugar in type 2 diabetes
Disease control OngoingThis phase 3 trial tests a new drug called JY09 in 270 adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. Participants receive either JY09 or a placebo injection every two weeks for up to 54 weeks. The main goal is to see if JY09 lowe…
Phase 3 • Sponsor: Beijing Dongfang Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:31 UTC